Orbital Vascular Inflammation in Ischemic Optic Neuropathy and Giant Cell Arteritis (VISION-GCA)
Status
Conditions
Treatments
Details and patient eligibility
About
Giant cell arteritis (GCA) is an inflammation of the blood vessels. A dangerous complication is sudden vision loss due to insufficient blood supply to the optic nerve. However, it is often difficult to distinguish acute vision loss due to GCA from a similar condition of insufficient blood supply to the optic nerve, called NAION. Quick treatment with anti-inflammatory medication is needed in case of GCA to prevent vision loss on the eye and other serious complications. Patients with NAION have no benefit of the medication, but can have serious side effects, why it is very important to differentiate between these conditions.
In this project, the investigators will use FDG PET/MRI with Black Blood (BB) sequences and OCT-imaging to study patients with GCA and/or ischemic optic nerve disease. The investigators will look for signs of inflammation in and around the small vessels of the orbit using PET/MRI and study subtle retinal changes using OCT images.
The investigators want to answer the following research questions:
Do patients with ischemic optic nerve disease and GCA show signs of inflammation in the orbital vessel wall on PET/MRI-scans, that are not present in patients with NAION?
Do GCA patients without vision loss, but with signs of orbital vessel wall inflammation on PET/MRI-scans, have a higher risk of later vision loss than GCA patients without?
Can subtle changes in the retina, detectable through OCT, help distinguish between GCA-related vision loss and NAION?
This will, to our knowledge, be the first study to systematically use FDG PET/MRI BB-scans to illuminate vascular changes in the orbit of patients with GCA and/or ischemic optic nerve disease. The results may improve diagnosis and treatment of GCA and NAION in the future. The investigators hope that this will help prevent blindness and other serious complications in patients with GCA, while also avoiding unnecessary treatments for patients with NAION.
Full description
Rationale and problem statement:
Giant cell arteritis (GCA) is an immune-driven inflammatory condition affecting the walls of blood vessels. Untreated, GCA can cause vessel wall thickening severe enough to reduce blood flow to various organs. One of the most feared complications is arteritic anterior ischemic optic neuropathy (A-AION), where the anterior part of the optic nerve loses its blood supply, resulting in sudden and often permanent vision loss.
It is crucial to distinguish A-AION from the much more common non-arteritic AION (NAION), since the correct diagnosis directly determines treatment. High-dose corticosteroids must be started immediately when GCA is suspected, in order to reduce the risk of vision loss in the other eye and other severe complications such as stroke or aortic dissection. In contrast, corticosteroid treatment does not benefit patients with NAION and should be avoided because of its significant short- and long-term side effects. However, it remains clinically very difficult to distinguish between A-AION and NAION, even with current diagnostic tools. Furthermore, fundamental knowledge about the vascular changes underlying ischemic optic neuropathy is still lacking.
Imaging background:
18F-Fluorodeoxyglucose (FDG) is a radiolabeled sugar analogue that highlights areas with increased metabolic activity, including inflammatory processes. Previous studies have shown increased FDG uptake in the walls of large and medium-sized arteries in the trunk and skull of GCA patients, but not in the small orbital vessels that supply the eye and optic nerve. Vessel wall inflammation also causes endothelial leakage and thickening, which can be visualized by Magnetic Resonance Imaging (MRI). Prior studies using orbital MRI with Black Blood (BB) sequences have demonstrated thickening and contrast enhancement of orbital vessels in GCA patients.
In addition, smaller studies suggest that patients with ischemic optic neuropathy may have subtle structural changes in the retina, visible on Optical Coherence Tomography (OCT) scans, with different patterns seen in A-AION versus NAION. The frequency and clinical significance of these changes remain poorly understood.
Study objectives:
The main goal of this project is to investigate orbital vessel inflammation in patients with ischemic optic neuropathy and GCA, specifically by measuring sugar metabolism (FDG uptake), endothelial permeability (contrast enhancement), and vessel wall thickening. The investigators will also determine whether these changes differ between A-AION and NAION. Furthermore, the investigators aim to study the occurence of subtle retinal changes, particularly paracentral acute middle maculopathy (PAMM) and intra- or subretinal fluid (IRF/SRF), and whether these occur with different frequencies in A-AION compared to NAION.
The study builds on the following hypotheses:
That patients with A-AION show increased FDG uptake, endothelial leakage, and vessel wall thickening in the orbital vessels supplying the eye and optic nerve, as signs of vascular inflammation, and that these changes are not present in NAION.
That GCA patients without vision loss but with signs of orbital vascular inflammation are at increased risk of later vision loss, compared with GCA patients without orbital vascular inflammation.
That subtle retinal changes are common in ischemic optic neuropathy and can function as specific biomarkers to distinguish between A-AION and NAION, thus improving early diagnosis and treatment.
Endpoints:
Substudy 1 (PET/MRI for A-AION vs NAION):
Primary endpoint: FDG uptake, endothelial leakage, and vessel wall thickening in the direct vascular supply of the eye and optic nerve.
Secondary/exploratory endpoints: Correlation with final clinical diagnosis; assessment of FDG uptake and vessel changes in other cranial arteries; characterization of orbital and optic nerve structural changes in NAION.
Substudy 2 (GCA without vision loss):
Primary endpoint: Incidence of ocular complications after 6 months (and possibly again after 2 years) in patients with orbital vascular inflammation versus those without.
Secondary/exploratory endpoints: Frequency and extent of orbital vessel inflammation; occurrence of subclinical structural/functional eye changes and retinal abnormalities (e.g., PAMM, IRF/SRF) in correspondance with orbital vascular inflammation.
Substudy 3 (Retinal biomarkers for A-AION vs NAION):
Primary endpoint: Occurrence of PAMM and IRF/SRF in ischemic optic neuropathy and correlation with the final diagnosis of A-AION versus NAION.
Secondary/exploratory endpoints: Association between retinal abnormalities and orbital inflammation.
Significance:
This study will, to our knowledge, be the first to investigate FDG uptake and endothelial dysfunction in the orbital vessels supplying the eye and optic nerve as markers of inflammation in ischemic optic neuropathy and GCA. It will also be the first large-scale study to examine the relationship between retinal changes (PAMM, IRF/SRF) and final diagnosis of A-AION or NAION.
Results may provide crucial insights into the pathophysiology of ischemic optic neuropathy and GCA, improving diagnostic accuracy and clinical management of both conditions. The findings could help prevent serious complications such as blindness, stroke, or aortic dissection in GCA patients and reduce unnecessary tests and immunosuppressive treatment in NAION patients. Furthermore, by identifying subclinical orbital inflammation, this project may contribute to improved risk stratification and personalized treatment strategies for GCA patients.
Background and literature review:
GCA is a systemic vasculitis affecting large and medium-sized arteries, often associated with polymyalgia rheumatica (PMR), and seen almost exclusively in people over 50. Incidence is highest in Scandinavia, at ~22 cases per 100,000 per year in this age group. Pathogenesis involves an autoimmune response with dysregulated T-cell activation, local dendritic cells, and pro-inflammatory cytokines (IL-1, IL-6, TNF), leading to formation of giant cells, vessel wall damage, and fibrotic remodeling.
Clinically, GCA can cause diverse symptoms, but untreated cases may result in sudden vision loss (A-AION) or systemic complications. Diagnosis is currently based on temporal artery biopsy and imaging methods such as ultrasound (halo and compression signs), MRI (contrast enhancement of vessel walls), and FDG PET (increased uptake in inflamed arteries). Orbital MRI BB has shown subclinical changes, including optic nerve sheath enhancement, in GCA patients without visual symptoms.
OCT imaging has identified ischemic retinal changes such as PAMM and IRF/SRF, which appear to differ between A-AION and NAION. Early data suggest these may serve as highly specific biomarkers for differentiating between the two, but findings require validation in larger, homogeneous cohorts. Since OCT is widely available and non-invasive, validated retinal biomarkers could become essential for rapid diagnosis of ischemic optic neuropathy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
For AION group:
- Clinical suspicion of newly onset ischemic optic neuropathy (A-AION or NA-AION), defined by ipsilateral findings of: Papilledema; Relevant visual impairment measured by visual acuity and/or visual field; Relative afferent pupillary defect (RAPD), except if mydriatic agents have been administered or if bilateral optic neuropathy is present.
- Age ≥ 50 years
For GCA group:
- Clinically- and ultrasound-confirmed, newly diagnosed GCA
- Absence of visual changes related to GCA in one or both eyes, including: Transient vision loss; permanent vision loss; transient double vision; permanent double vision
- Age ≥ 50 years
Exclusion criteria
- Ferromagnetic implants
- Severe renal impairment with eGFR < 30 mL/min/1.73m²
- Allergy to MRI contrast agents
- Severe claustrophobia
- Pregnancy or breastfeeding
- Previously documented ipsilateral optic neuropathy or giant cell arteritis
- More than 5 days of treatment with prednisolone prior to inclusion
Trial design
122 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal